{"id":16910,"date":"2026-05-19T07:49:22","date_gmt":"2026-05-19T14:49:22","guid":{"rendered":"https:\/\/elixirmedical.com\/?p=16910"},"modified":"2026-05-19T08:32:01","modified_gmt":"2026-05-19T15:32:01","slug":"europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death","status":"publish","type":"post","link":"https:\/\/elixirmedical.com\/id\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\/","title":{"rendered":"EuroPCR 2026: Elixir Medical\u2019s DynamX\u00ae Bioadaptor Demonstrates Significantly Lower Event Rates Than Drug-Eluting Stent in Long-Term Follow-Up, Including Reduction in Cardiovascular Death"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"16910\" class=\"elementor elementor-16910\" data-elementor-settings=\"{&quot;ha_cmc_init_switcher&quot;:&quot;no&quot;}\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-42dd510a elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"42dd510a\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-4e86aaec\" data-id=\"4e86aaec\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-7b9b726 elementor-widget elementor-widget-heading\" data-id=\"7b9b726\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h4 class=\"elementor-heading-title elementor-size-default\">Significantly lower TLF rates (2.8% versus 7.8%, p=0.020) with DynamX\u00ae compared to Resolute Onyx DES with no new events in bioadaptor arm between 3 and 4 years<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3e02624 elementor-widget elementor-widget-heading\" data-id=\"3e02624\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h4 class=\"elementor-heading-title elementor-size-default\">88% reduction in Cardiovascular Death (0.5% versus 3.7%, p=0.020) with DynamX\u00ae compared to DES<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bc93971 elementor-widget elementor-widget-text-editor\" data-id=\"bc93971\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>PARIS \u2013 May 19, 2026 \u2013 <\/strong><a href=\"http:\/\/elixirmedical.com\">Elixir Medical<\/a>, a developer of transformative technologies to treat cardiovascular and peripheral disease, today announced four-year results from the large 445-patient BIOADAPTOR Randomized Controlled Trial (RCT), comparing the DynamX<sup>\u00ae<\/sup> Coronary Bioadaptor System to standard of care Resolute Onyx\u2122 Drug-Eluting Stent (DES) at 34 centers in Japan, Europe, and New Zealand. The data were presented at a late-breaking clinical trial session during the EuroPCR 2026 conference in Paris.<\/p><p>\u201cInterventional cardiologists typically use a drug-eluting stent (DES) during percutaneous coronary intervention (PCI) to open the heart blockage and keep the artery open. These interlocked mesh-like tubes, however, permanently cage the artery, limiting its function and contributing to an annual 2-3% increase in adverse clinical events over time,\u201d &#8211; said Professor Stefan Verheye, M.D., Ph.D., interventional cardiologist at ZNA Cardiovascular Center in Antwerp, Belgium and leading DynamX<sup>\u00ae<\/sup> investigator. \u201cThe bioadaptor is a new type of unlocking, adaptive implant designed to keep the artery open while restoring normal vessel function, its compliance and pulsatility.\u201d<\/p><p>Late-breaking four-year results presented at EuroPCR highlight durable clinical outcomes with the DynamX<sup>\u00ae<\/sup> bioadaptor, with no new target lesion failure (TLF) or cardiovascular death (CVD) events observed between years three and four, maintaining a very low plateauing rate of adverse events compared to the continued annual increase seen with DES.<\/p><p>DynamX<sup>\u00ae<\/sup> demonstrated a 66% lower TLF rate (2.8% versus 7.8%; p=0.020) compared to DES, reflecting significant clinical benefit and long-term durability of PCI treatment with bioadaptor. The TLF reduction was driven by improvement across all components of the device-related combined endpoint, including:<\/p><ul><li>88% lower cardiovascular death (0.5% versus 3.7%, p=0.020), a statistically significant reduction<\/li><li>Numerically lower target vessel myocardial infarction (0.9% versus 1.8%)<\/li><li>Numerically lower clinically driven target lesion revascularization (1.4% versus 2.8%)<\/li><\/ul><p>These findings highlight a key differentiation of the bioadaptor implant from drug-eluting stents: while DES outcomes continue to accrue adverse events over time, DynamX<sup>\u00ae<\/sup> demonstrates stabilization of event rates following restoration of vessel function at 6 months post-procedure.<\/p><p>Substantial clinical improvement was also observed in the left anterior descending (LAD) artery, with TLF rates dramatically lower with DynamX<sup>\u00ae<\/sup> compared to DES (2.7% versus 10.6%; p=0.021), potentially reflecting an amplified impact of restoring vessel function in this hemodynamically critical coronary vessel responsible for about 50% of heart blood supply.<\/p><p>\u201cThe DynamX<sup>\u00ae<\/sup> bioadaptor represents a significant advancement in PCI by providing functional restoration of the artery,\u201d \u2013 remarked Shigeru Saito, M.D., trial principal investigator and director of the Division of Cardiology and Catheterization Laboratory at Shonan Kamakura General Hospital in Kamakura, Japan. \u201cFurthermore, the significant finding in reducing cardiovascular mortality marks a major achievement in how we treat cardiovascular disease and improve patient outcomes.\u201d<\/p><p>PCI procedures have been successful at improving the conductance of blood through diseased, blocked coronary arteries. Stents establish luminal diameter and improve the acute mechanical result of PCI compared to balloon angioplasty. However, DES do not restore the physiology of the vessel wall because they create rigid scaffolding. This constrains vessel elasticity and prevents return to a more normal, pulsatile function.<\/p><p>The DynamX<sup>\u00ae<\/sup> bioadaptor first achieves the initial objective of opening the artery in establishing luminal diameter to improve blood flow. Unlike DES, it transitions to a different structure following an initial period of healing where it unlocks and provides the essential radial dynamic support to the diseased artery, allowing the treated segment to recover pulsatility and compliance.<\/p><p>\u201cThe four-year BIOADAPTOR-RCT data presented today, and the results from the 2,400 patient INIFINITY-SWEDEHEART RCT have shown consistently across multiple randomized clinical trials significantly lower, plateauing clinical events with DynamX<sup>\u00ae<\/sup> bioadaptor compared to DES treatment, demonstrating the clear benefit of restoring a key function of arteries, hemodynamic modulation, with this breakthrough technology.\u201d &#8211; said Motasim Sirhan, CEO of Elixir Medical.<\/p><p><strong>About BIOADAPTOR RCT Trial<\/strong><\/p><p>The BIOADAPTOR RCT is an international, single-blind, randomized controlled (1:1) trial comparing a sirolimus-eluting bioadaptor with a contemporary zotarolimus-eluting stent in 445 patients in 34 centers in Japan, Europe, and New Zealand. Both arms had large randomized multi-modality imaging subgroups of 50 patients each to document standard effectiveness benchmarks of establishing and maintaining artery flow lumen measured by percent diameter stenosis (%DS) and late lumen loss (LLL), and the new effectiveness benchmarks of restoring artery hemodynamic modulation, including pulsatility, vessel compliance, adaptive flow volume, and plaque stabilization and regression. Clinical follow-up will continue through five years.<\/p><p>BIOADAPTOR RCT trial is part of Elixir Medical\u2019s robust DynamX<sup>\u00ae<\/sup> bioadaptor clinical evidence program consisting of nine company-sponsored and investigator-initiated studies involving over 9,000 patients.<\/p><p><strong>About DynamX<sup>\u00ae<\/sup> Sirolimus Eluting Coronary Bioadaptor System<\/strong><\/p><p>The DynamX<sup>\u00ae<\/sup> bioadaptor is the first coronary implant technology designed to restore coronary artery hemodynamic modulation as demonstrated by restored vessel pulsatility, compliance, and adaptive increase in blood flow volume, and providing plaque stabilization and regression. With its unique mechanism of action (MOA), it addresses the shortcomings of drug-eluting stents and bioresorbable scaffolds (BRS) with remarkably low clinical event rates that showed a plateau from six months through four-year clinical follow-up.\u00a0<\/p><p>The DynamX<sup>\u00ae<\/sup> Sirolimus Eluting Coronary Bioadaptor System is CE-marked. The DynamX<sup>\u00ae<\/sup> Sirolimus Eluting Coronary Bioadaptor System is an investigational device, limited by Federal (or United States) law to investigational use.<\/p><p><strong>About Elixir Medical<\/strong><\/p><p>Elixir Medical Corporation, a privately held company based in Milpitas, California, develops disruptive platforms to treat coronary and peripheral artery disease. Our transformative technologies have multiple applications across the cardiovascular space capable of delivering improved clinical outcomes for millions of patients. Elixir Medical was named to Fast Company\u2019s prestigious list of the World\u2019s Most Innovative Companies of 2025. Visit us at <a href=\"http:\/\/www.elixirmedical.com\">www.elixirmedical.com<\/a> and on <a href=\"https:\/\/www.linkedin.com\/company\/elixir-medical-corporation\/\">LinkedIn<\/a>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2f5322e elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"2f5322e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2dc6cce elementor-widget elementor-widget-text-editor\" data-id=\"2dc6cce\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Media Contact<\/strong><\/p><p>Richard Laermer, RLM PR<\/p><p><a href=\"mailto:elixir@rlmpr.com\">elixir@rlmpr.com<\/a><\/p><p>(212) 741-5106 X 216<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p> Elixir Medical announced four-year results from the large 445-patient BIOADAPTOR Randomized Controlled Trial (RCT), comparing the DynamX\u00ae Coronary Bioadaptor System to standard of care Resolute Onyx\u2122 Drug-Eluting Stent (DES) at 34 centers presented at a late-breaking clinical trial session during EuroPCR 2026.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_metasync_otto_title":"","_metasync_otto_description":"","_metasync_otto_keywords":"","_metasync_otto_og_title":"","_metasync_otto_og_description":"","_metasync_otto_twitter_title":"","_metasync_otto_twitter_description":"","rank_math_title":"","rank_math_description":"","_aioseo_title":"","_aioseo_description":"","_metasync_seo_title":"","_metasync_seo_desc":"","_metasync_breadcrumb_title":"","_metasync_primary_category":0,"_metasync_primary_product_cat":0,"_metasync_otto_disabled":"","_metasync_hreflang":"","_metasync_plugin_sync_ts":"","_metasync_robots_advanced":"","footnotes":""},"categories":[46],"tags":[],"class_list":["post-16910","post","type-post","status-publish","format-standard","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BIOADAPTOR RCT 4-Year Results | Elixir Medical<\/title>\n<meta name=\"description\" content=\"Elixir Medical announced four-year results from the BIOADAPTOR RCT comparing the DynamX\u00ae Coronary Bioadaptor System to standard of care DES.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/elixirmedical.com\/id\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\/\" \/>\n<meta property=\"og:locale\" content=\"id_ID\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BIOADAPTOR RCT 4-Year Results | Elixir Medical\" \/>\n<meta property=\"og:description\" content=\"Elixir Medical announced four-year results from the BIOADAPTOR RCT comparing the DynamX\u00ae Coronary Bioadaptor System to standard of care DES.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/elixirmedical.com\/id\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\/\" \/>\n<meta property=\"og:site_name\" content=\"Elixir Medical\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/elixirmedicalinc\" \/>\n<meta name=\"author\" content=\"elixirnewdev\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ditulis oleh\" \/>\n\t<meta name=\"twitter:data1\" content=\"elixirnewdev\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimasi waktu membaca\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 menit\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\\\/\"},\"author\":{\"name\":\"elixirnewdev\",\"@id\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/#\\\/schema\\\/person\\\/e27019787efed2242c7a24b2022d1caa\"},\"headline\":\"EuroPCR 2026: Elixir Medical\u2019s DynamX\u00ae Bioadaptor Demonstrates Significantly Lower Event Rates Than Drug-Eluting Stent in Long-Term Follow-Up, Including Reduction in Cardiovascular Death\",\"datePublished\":\"2026-05-19T14:49:22+00:00\",\"dateModified\":\"2026-05-19T15:32:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\\\/\"},\"wordCount\":967,\"publisher\":{\"@id\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/#organization\"},\"articleSection\":[\"News\"],\"inLanguage\":\"id\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\\\/\",\"url\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\\\/\",\"name\":\"BIOADAPTOR RCT 4-Year Results | Elixir Medical\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/#website\"},\"datePublished\":\"2026-05-19T14:49:22+00:00\",\"dateModified\":\"2026-05-19T15:32:01+00:00\",\"description\":\"Elixir Medical announced four-year results from the BIOADAPTOR RCT comparing the DynamX\u00ae Coronary Bioadaptor System to standard of care DES.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\\\/#breadcrumb\"},\"inLanguage\":\"id\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/elixirmedical.com\\\/id\\\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EuroPCR 2026: Elixir Medical\u2019s DynamX\u00ae Bioadaptor Demonstrates Significantly Lower Event Rates Than Drug-Eluting Stent in Long-Term Follow-Up, Including Reduction in Cardiovascular Death\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/#website\",\"url\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/\",\"name\":\"Elixir Medical\",\"description\":\"Transformation Unlocked\",\"publisher\":{\"@id\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"id\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/#organization\",\"name\":\"Elixir Medical\",\"url\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"id\",\"@id\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/elixirmedical.com\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/New-Elixir-Logo.png\",\"contentUrl\":\"https:\\\/\\\/elixirmedical.com\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/New-Elixir-Logo.png\",\"width\":5550,\"height\":1870,\"caption\":\"Elixir Medical\"},\"image\":{\"@id\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/elixirmedicalinc\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/#\\\/schema\\\/person\\\/e27019787efed2242c7a24b2022d1caa\",\"name\":\"elixirnewdev\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"id\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/53ca892e1ec140b1bd2851c353f10f796a8784f55d2c50b792402975a5afcb8b?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/53ca892e1ec140b1bd2851c353f10f796a8784f55d2c50b792402975a5afcb8b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/53ca892e1ec140b1bd2851c353f10f796a8784f55d2c50b792402975a5afcb8b?s=96&d=mm&r=g\",\"caption\":\"elixirnewdev\"},\"sameAs\":[\"https:\\\/\\\/elixirmedical.com\"],\"url\":\"https:\\\/\\\/elixirmedical.com\\\/id\\\/author\\\/elixirnewdev\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BIOADAPTOR RCT 4-Year Results | Elixir Medical","description":"Elixir Medical announced four-year results from the BIOADAPTOR RCT comparing the DynamX\u00ae Coronary Bioadaptor System to standard of care DES.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/elixirmedical.com\/id\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\/","og_locale":"id_ID","og_type":"article","og_title":"BIOADAPTOR RCT 4-Year Results | Elixir Medical","og_description":"Elixir Medical announced four-year results from the BIOADAPTOR RCT comparing the DynamX\u00ae Coronary Bioadaptor System to standard of care DES.","og_url":"https:\/\/elixirmedical.com\/id\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\/","og_site_name":"Elixir Medical","article_publisher":"https:\/\/www.facebook.com\/elixirmedicalinc","author":"elixirnewdev","twitter_card":"summary_large_image","twitter_misc":{"Ditulis oleh":"elixirnewdev","Estimasi waktu membaca":"5 menit"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/elixirmedical.com\/id\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\/#article","isPartOf":{"@id":"https:\/\/elixirmedical.com\/id\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\/"},"author":{"name":"elixirnewdev","@id":"https:\/\/elixirmedical.com\/id\/#\/schema\/person\/e27019787efed2242c7a24b2022d1caa"},"headline":"EuroPCR 2026: Elixir Medical\u2019s DynamX\u00ae Bioadaptor Demonstrates Significantly Lower Event Rates Than Drug-Eluting Stent in Long-Term Follow-Up, Including Reduction in Cardiovascular Death","datePublished":"2026-05-19T14:49:22+00:00","dateModified":"2026-05-19T15:32:01+00:00","mainEntityOfPage":{"@id":"https:\/\/elixirmedical.com\/id\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\/"},"wordCount":967,"publisher":{"@id":"https:\/\/elixirmedical.com\/id\/#organization"},"articleSection":["News"],"inLanguage":"id"},{"@type":"WebPage","@id":"https:\/\/elixirmedical.com\/id\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\/","url":"https:\/\/elixirmedical.com\/id\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\/","name":"BIOADAPTOR RCT 4-Year Results | Elixir Medical","isPartOf":{"@id":"https:\/\/elixirmedical.com\/id\/#website"},"datePublished":"2026-05-19T14:49:22+00:00","dateModified":"2026-05-19T15:32:01+00:00","description":"Elixir Medical announced four-year results from the BIOADAPTOR RCT comparing the DynamX\u00ae Coronary Bioadaptor System to standard of care DES.","breadcrumb":{"@id":"https:\/\/elixirmedical.com\/id\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\/#breadcrumb"},"inLanguage":"id","potentialAction":[{"@type":"ReadAction","target":["https:\/\/elixirmedical.com\/id\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/elixirmedical.com\/id\/europcr-2026-elixir-medicals-dynamx-bioadaptor-demonstrates-significantly-lower-event-rates-than-drug-eluting-stent-in-long-term-follow-up-including-reduction-in-cardiovascular-death\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/elixirmedical.com\/id\/"},{"@type":"ListItem","position":2,"name":"EuroPCR 2026: Elixir Medical\u2019s DynamX\u00ae Bioadaptor Demonstrates Significantly Lower Event Rates Than Drug-Eluting Stent in Long-Term Follow-Up, Including Reduction in Cardiovascular Death"}]},{"@type":"WebSite","@id":"https:\/\/elixirmedical.com\/id\/#website","url":"https:\/\/elixirmedical.com\/id\/","name":"Elixir Medical","description":"Transformation Unlocked","publisher":{"@id":"https:\/\/elixirmedical.com\/id\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/elixirmedical.com\/id\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"id"},{"@type":"Organization","@id":"https:\/\/elixirmedical.com\/id\/#organization","name":"Elixir Medical","url":"https:\/\/elixirmedical.com\/id\/","logo":{"@type":"ImageObject","inLanguage":"id","@id":"https:\/\/elixirmedical.com\/id\/#\/schema\/logo\/image\/","url":"https:\/\/elixirmedical.com\/wp-content\/uploads\/2023\/09\/New-Elixir-Logo.png","contentUrl":"https:\/\/elixirmedical.com\/wp-content\/uploads\/2023\/09\/New-Elixir-Logo.png","width":5550,"height":1870,"caption":"Elixir Medical"},"image":{"@id":"https:\/\/elixirmedical.com\/id\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/elixirmedicalinc"]},{"@type":"Person","@id":"https:\/\/elixirmedical.com\/id\/#\/schema\/person\/e27019787efed2242c7a24b2022d1caa","name":"elixirnewdev","image":{"@type":"ImageObject","inLanguage":"id","@id":"https:\/\/secure.gravatar.com\/avatar\/53ca892e1ec140b1bd2851c353f10f796a8784f55d2c50b792402975a5afcb8b?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/53ca892e1ec140b1bd2851c353f10f796a8784f55d2c50b792402975a5afcb8b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/53ca892e1ec140b1bd2851c353f10f796a8784f55d2c50b792402975a5afcb8b?s=96&d=mm&r=g","caption":"elixirnewdev"},"sameAs":["https:\/\/elixirmedical.com"],"url":"https:\/\/elixirmedical.com\/id\/author\/elixirnewdev\/"}]}},"acf":[],"featured_image_src":null,"featured_image_src_square":null,"author_info":{"display_name":"elixirnewdev","author_link":"https:\/\/elixirmedical.com\/id\/author\/elixirnewdev\/"},"_links":{"self":[{"href":"https:\/\/elixirmedical.com\/id\/wp-json\/wp\/v2\/posts\/16910","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/elixirmedical.com\/id\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/elixirmedical.com\/id\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/elixirmedical.com\/id\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/elixirmedical.com\/id\/wp-json\/wp\/v2\/comments?post=16910"}],"version-history":[{"count":0,"href":"https:\/\/elixirmedical.com\/id\/wp-json\/wp\/v2\/posts\/16910\/revisions"}],"wp:attachment":[{"href":"https:\/\/elixirmedical.com\/id\/wp-json\/wp\/v2\/media?parent=16910"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/elixirmedical.com\/id\/wp-json\/wp\/v2\/categories?post=16910"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/elixirmedical.com\/id\/wp-json\/wp\/v2\/tags?post=16910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}